Affiliation:
1. RABTA Hospital, Tunis, Tunisia
2. University of Tunis El Manar, Tunisia
Abstract
This report describes a case of facial hyperpigmentation in a patient with Crohn’s disease receiving adalimumab, a tumor necrosis factor (TNF)-alpha inhibitor. The onset of hyperpigmentation coincided with adalimumab administration, and its discontinuation resulted in significant improvement. Histopathological findings suggest a postinflammatory process at the dermo-epidermal junction. However, the precise mechanism remains unclear.